To read the full article sign up for free or sign in.

Valneva banks $130M as Pfizer buys into Lyme disease vaccine program

April 30, 2020

DUBLIN – Shares in Valneva SE rose by as much as 32% during early trading April 30 on news that Pfizer Inc. is paying $130 million up front to in-license its Lyme disease candidate vaccine, VLA-15.

BioWorld Deals and M&A Infection Coronavirus

Today's news in brief

BioWorld

BioWorld briefs for March 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 31, 2025

CMV history cited in DMD liver death on Sarepta’s Elevidys

BioWorld

Wall Street was weighing the gravity of the death from acute liver failure of a patient who was treated for Duchenne muscular dystrophy (DMD) with Sarepta...

UK government abolishes NHS England

BioWorld MedTech

In a move that surprised many across the health care sector, the U.K. government decided to scrap NHS England, the body which runs the national health service...

Sofinnova adds €165M to boost European startups

BioWorld

Leading pharma companies have pitched into Sofinnova Partners’ new accelerator fund, which has exceeded the target and closed at €165 million (US$180 million). In...